



# BISOPROLOL Solution

- **Indicated for** treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, diuretics, and optionally cardiac glycosides, treatment of hypertension and angina

Available strength: 2.5mg/5 ml  
(dosage in the range of 1.25 - 10mg can be administered)

## Benefit for target population

- Product containing Bisoprolol in form of oral liquid (suspension) is intended for patients with swallowing difficulties
- It can be used as substitution for tablets to enhance patient compliance
- Another advantage is to lower pill burden

## Reference markets

- Bisoprolol remains the largest Beta blocker with 2.0b tablets sold (MAT Q2 2022) as per IQVIA (EU27+UK)

Product for patients  
with swallowing  
difficulties or naso  
gastric tube

Ready-to-use  
suspension for adults

Easy dose via oral  
syringe



## Regulatory pathway

- Legal basis: Article 10(3) hybrid application

## Development status

- Registration batches ready
- Clinical Strategy: bioequivalence study vs. tablets
- EU dossier available from Q2/2023

## Partnership options

- Product is available for out-licensing in selected markets in Europe or co-development on exclusive or semi-exclusive base
- Dossier can be adjusted to markets outside Europe based on request

**DISCLAIMER:** Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.